High ALK Receptor Tyrosine Kinase Expression Supersedes ALK Mutation as a Determining Factor of an Unfavorable Phenotype in Primary Neuroblastoma
Authors:
- Johannes H. SchulteJSJohannes H. Schulte
- Hagen S. BachmannHBHagen S. Bachmann
- Bent BrockmeyerBBBent Brockmeyer
- Katleen DePreterKDKatleen DePreter
- André OberthürAOAndré Oberthür
- Sandra AckermannSASandra Ackermann
- Yvonne KahlertYKYvonne Kahlert
- Kristian PajtlerKPKristian Pajtler
- Jessica TheissenJTJessica Theissen
- Frank WestermannFWFrank Westermann
- Jo VandesompeleJVJo Vandesompele
- Frank SpelemanFSFrank Speleman
Open Access
- 31 July 2011
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 17 (15) , 5082-5092
Abstract
Purpose: Genomic alterations of the anaplastic lymphoma kinase (ALK) gene have been postulated to contribute to neuroblastoma pathogenesis. This study aimed to determine the interrelation of ALK mutations, ALK expression levels, and clinical phenotype in primary neuroblastoma. Experimental Design: The genomic ALK status and global gene expression patterns were examined in 263 primary neuroblastomas. Allele-specific ALK expression was determined by cDNA cloning and sequencing. Associations of genomic ALK alterations and ALK expression levels with clinical phenotypes and transcriptomic profiles were compared. Results: Nonsynonymous point mutations of ALK were detected in 21 of 263 neuroblastomas (8%). Tumors with ALK mutations exhibited about 2-fold elevated median ALK mRNA levels in comparison with tumors with wild-type (WT) ALK. Unexpectedly, the WT allele was preferentially expressed in 12 of 21 mutated tumors. Whereas survival of patients with ALK mutated tumors was significantly worse as compared with the entire cohort of WT ALK patients, it was similarly poor in patients with WT ALK tumors in which ALK expression was as high as in ALK mutated neuroblastomas. Global gene expression patterns of tumors with ALK mutations or with high-level WT ALK expression were highly similar, and suggested that ALK may be involved in cellular proliferation in primary neuroblastoma. Conclusions: Primary neuroblastomas with mutated ALK exhibit high ALK expression levels and strongly resemble neuroblastomas with elevated WT ALK expression levels in both their clinical and molecular phenotypes. These data suggest that high levels of mutated and WT ALK mediate similar molecular functions that may contribute to a malignant phenotype in primary neuroblastoma. Clin Cancer Res; 17(15); 5082–92. ©2011 AACR.Keywords
All Related Versions
This publication has 37 references indexed in Scilit:
- Molecular Characterization and Classification of NeuroblastomaFuture Oncology, 2009
- Anaplastic lymphoma kinase: role in cancer pathogenesis and small-molecule inhibitor development for therapyExpert Review of Anticancer Therapy, 2009
- Somatic and germline activating mutations of the ALK kinase receptor in neuroblastomaNature, 2008
- Activating mutations in ALK provide a therapeutic target in neuroblastomaNature, 2008
- Oncogenic mutations of ALK kinase in neuroblastomaNature, 2008
- Identification of ALK as a major familial neuroblastoma predisposition geneNature, 2008
- NeuroblastomaThe Lancet, 2007
- ALK receptor tyrosine kinase promotes cell growth and neurite outgrowthJournal of Cell Science, 2004
- Neuroblastoma: biological insights into a clinical enigmaNature Reviews Cancer, 2003
- Activation of Anaplastic Lymphoma Kinase Receptor Tyrosine Kinase Induces Neuronal Differentiation through the Mitogen-activated Protein Kinase PathwayJournal of Biological Chemistry, 2001